To do this, we established the LLC subcutaneous tumor model in Acod1f/fLyz2cre− (HO−) and Acod1f/fLyz2cre+ (HO+) mice, and the neutralizing CD8 antibody was used to deplete CD8+ T cells in the mice. The gene discussed is CD8A; the disease is neoplasm.